You are here

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Last updated on March 25, 2019

FOR MORE INFORMATION
Study Location
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, 233004 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.

- ER positive.

- The patient must be postmenopausal woman.

- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will
switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will
necessarily precede and will be independent of the decision to enroll patients in the
study).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving
Aromasin® treatment, there is evidence of a local relapse or distant metastasis of
breast cancer, or a second primary cancer.

- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase
inhibitors (not Aromasin®).

NCT01176916
Pfizer
Completed
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms, Breast Neoplasms
NCT03343054
All Genders
20+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now